March 9, Everest Medicines (HKG: 1952) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated…
International Women’s Day: Why Menopause May Be a Missed Cardiovascular Risk Window As International Women’s Day prompts renewed focus on women’s health, OMRON Healthcare has released a new Women’s Heart…
Formerra, LLC (Formerra), a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials, today announced the appointment of Tom Kelly as Chief Executive Officer (CEO). A seasoned…
– First glucokinase-activator (GKA) approval outside mainland China – Approval supports a differentiated approach to Type 2 diabetes (T2D) management – Hong Kong will serve as Hua Medicine’s launchpad for…
– Exhibition space fully secured prior to the show, reflecting strong exhibitor confidence in Northern Vietnam’s laboratory and scientific markets – Over 150 international and local exhibitors & brands confirmed…
CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the NMPA), pursuant…
Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a…
12 February 2026, Modern Dental Group Limited (Modern Dental or the Group, HKG: 3600), a leading global dental prosthetic device provider, is pleased to announce our new identity. This year,…
Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The…
Essex Bio-Technology Limited (EssexBio or the Company; HKG: 1061) today announces its successful participation in the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from 5 to 8 February…
According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (HKG: 1672).…
According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by…
On February 6, Distinct Healthcare Holdings Limited (Distinct Healthcare or the Company, Stock Code: 2677.HK), a leading player in China’s mid-to-high-end consumer healthcare services market, was successfully listed on the…
Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis…
According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price…
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into…
Industry recognition for the third consecutive year reinforces AGFA HealthCare’s clinician-first commitment, and leadership in empowering connected, high-performance imaging environments AGFA HealthCare today announced that it has been named Best…
Agreement Expands Access to Evonik’s CARE Brand Medical Grades in the U.S. and Canada Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik’s…
Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with…
Company reiterates focus on advancing ProLectin-M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative disease Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage…
